来自Gastrodia elata的化合物的设计,合成和神经保护活性 布鲁姆和博尔尼奥尔
Lijuan Zhi1, Huan Li1, Baimei Shi2
1Center Laboratory, Xi'an Mental Health Center, Xi'an, China.
Frontiers in pharmacology
|October 8, 2024
概括
来自传统中医药的新药分子显示神经保护作用. 化合物TB-2对PC12细胞的谷氨酸诱导损伤产生了显著的保护,这表明它有可能治疗脑缺血症.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 传统中国医药 传统中国医药
背景情况:
- 传统中医药 (TCM) Gastrodia elata Blume (GEB) 具有放松肝脏和散发风的特性.
- GEB成分提供神经保护,缓解疼痛和增强记忆.
- 醇有助于药物通过血脑屏障吸收药物,从而提高疗效.
研究的目的:
- 用复合中医分子化学方法设计新型药物分子.
- 探索复合中医药的现代化,以获得治疗效益.
- 研究合成化合物的神经保护潜力,以防止刺激毒性.
主要方法:
- 在PC12细胞上使用谷氨酸建立了激发性损伤模型.
- 用CCK-8试剂组评估细胞活力.
- 使用Genecards,Disgenet和OMIM数据库进行目标识别.
- 采用分子对接来预测化合物-目标相互作用.
主要成果:
- 合成的TB-1至TB-16化合物;TB-1,TB-2,TB-12和TB-16显示出安全性和神经保护潜力.
- 化合物TB-2对谷氨酸酸受损的PC12细胞表现出剂量依赖的保护作用.
- 网络药理学和分子对接确定了SRC,MAPK1和KDR作为脑缺血中TB-2的潜在目标.
结论:
- 化合物TB-2显示显著的神经保护作用对谷氨酸诱导的PC12细胞损伤.
- 这些发现表明,TB-2对诸如脑缺血等疾病具有治疗前景.
- 这项研究支持通过创新的分子设计现代化复合中医药.
更多相关视频
07:16Preparation of Gynura bicolor DC samples for High-Resolution Tandem Mass Spectrometry
Published on: February 2, 2024
512
07:36Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
Published on: December 23, 2022
1.5K
相关概念视频
Structure-Activity Relationships and Drug Design
676
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
676
Drug Discovery: Overview
7.6K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.6K
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.6K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.6K
